MAY 14·MoomooMed
Vivani Medical 1Q Loss $6.78M >VANI
Vivani Medical reported a first-quarter loss of $6.78 million. The article provides a concise financial update for the company.
StockHealthcare · Biotechnology
$VANI
Vivani Medical, Inc.
Price · $VANIvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $VANI in the last 7 days.
Insider · 30dFeed →
No SEC Form 4 filings for $VANI in the last 30 days.
Top stories · $VANIMore →
MAR 31·TipRanks
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the price target for Vivani Medical (VANI) to $3.50 from $4, while maintaining a Buy rating. This adjustment was made after the company reported its 2025 results, with the analyst citing an increased share count as the reason for the reduced target. Despite the target reduction, H.C. Wainwright believes Vivani Medical's NPM-139 has the potential to offer efficacy comparable to Wegovy with less frequent administration.
NOV 13·GlobeNewswire
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback ...